Literature DB >> 6432613

Hearing loss in Hunter's syndrome--mucopolysaccharidosis II.

J E Peck.   

Abstract

Hunter's syndrome [mucopolysaccharidosis II (MPS II)] is a genetic, metabolic disease of excessive mucopolysaccharide storage leading to mental and skeletal abnormalities, distinctive facial features, and increased incidence of hearing loss. However, the hearing impairment in MPS II has not been well described in the literature. This paper examines the auditory aspects of MPS II by reviewing the literature and by presenting two affected brothers. Each subject had mixed hearing disorders, fluctuating between moderate and severe degrees associated with recurrent middle ear effusions. Hearing loss appears to be a frequent concomitant of MPS II and is usually of mixed nature. The conductive component may persist after myringotomy. Aggressive audiological and otological management are required to enhance communicative development.

Entities:  

Mesh:

Year:  1984        PMID: 6432613     DOI: 10.1097/00003446-198407000-00009

Source DB:  PubMed          Journal:  Ear Hear        ISSN: 0196-0202            Impact factor:   3.570


  14 in total

1.  Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.

Authors:  Annerose Keilmann; Todsaporn Nakarat; Iain A Bruce; David Molter; Gunilla Malm
Journal:  J Inherit Metab Dis       Date:  2011-08-25       Impact factor: 4.982

2.  Hearing loss in Pompe disease revisited: results from a study of 24 children.

Authors:  Carine I van Capelle; Andre Goedegebure; Nienke C Homans; Hans L J Hoeve; Arnold J Reuser; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2010-07-02       Impact factor: 4.982

3.  Hearing in adults with Pompe disease.

Authors:  Nadine A M E van der Beek; Hans Verschuure; Arnold J J Reuser; Ans T van der Ploeg; Pieter A van Doorn; René M L Poublon
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

Review 4.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

5.  The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life.

Authors:  Mireia Raluy-Callado; Wen-Hung Chen; David A H Whiteman; Juanzhi Fang; Ingela Wiklund
Journal:  Orphanet J Rare Dis       Date:  2013-07-10       Impact factor: 4.123

6.  Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.

Authors:  Nathalie Guffon; Bénédicte Heron; Brigitte Chabrol; François Feillet; Vincent Montauban; Vassili Valayannopoulos
Journal:  Orphanet J Rare Dis       Date:  2015-04-12       Impact factor: 4.123

Review 7.  Calcium signaling via two-pore channels: local or global, that is the question.

Authors:  Michael X Zhu; Jianjie Ma; John Parrington; Peter J Calcraft; Antony Galione; A Mark Evans
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-16       Impact factor: 4.249

8.  Management of otolaryngological manifestations in mucopolysaccharidoses: our experience.

Authors:  M Mesolella; M Cimmino; E Cantone; A Marino; M Cozzolino; R Della Casa; G Parenti; M Iengo
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-08       Impact factor: 2.124

Review 9.  Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America.

Authors:  Roberto Giugliani; Martha Luz Solano Villarreal; C Araceli Arellano Valdez; Antonieta Mahfoud Hawilou; Norberto Guelbert; Luz Norela Correa Garzón; Ana Maria Martins; Angelina Acosta; Juan Francisco Cabello; Aída Lemes; Mara Lucia Schmitz Ferreira Santos; Hernán Amartino
Journal:  Genet Mol Biol       Date:  2014-06       Impact factor: 1.771

10.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.